Document:

exv10w10wb

Exhibit 10.10(b)

Second Amendment to Exclusive Patent License Agreement

Between

University of Arizona and Oncothyreon, Inc.

Effective 15 September 2005

     This Second Amendment (“Second Amendment”), effective on the date of last authorized signature
affixed hereto, is by and between the Arizona Board of Regents on behalf of the University of
Arizona, having an office at 888 N. Euclid Avenue, Room 204, Tucson, Arizona 85721 (“LICENSOR”),
and Oncothyreon, Inc., having its principal office at 2601 Fourth Avenue, Suite 500, Seattle,
Washington 98121 (“LICENSEE”).

     WHEREAS, LICENSOR and Pro1X Pharmaceuticals Corporation, which was subsequently acquired by
LICENSEE, entered into an Exclusive Patent License Agreement, effective 15 September 2005
(“Agreement”), that, by assignment of the Agreement, granted to LICENSEE exclusive rights in
Licensed Patents described in Schedule A pursuant to Section 2.3 of the Agreement; and

     WHEREAS, LICENSOR and LICENSEE previously amended Schedule A of the Agreement to add certain
Licensed Patents to the Agreement pursuant to the First Amendment to the Agreement, which amendment
was effective on 28 November 2008 (“First Amendment”); and

     WHEREAS, LICENSOR and LICENSEE wish to further amend Schedule A of the Agreement to delete
certain Licensed Patents from the Agreement.

     NOW, THEREFORE, the parties agree as follows:

     1. Schedule A (as amended by the First Amendment) shall be replaced in its entirety as
follows:

Schedule A

	 	 	 	 	 	 	 	 	 
	Serial No.	 	Territory	 	Title	 	Filing Date	 	Status
	10/288,888

	 	US
	 	N-Oxides and
Derivatives of
Melphalan for
Treating Diseased
States Associated
With Hypoxia
Inducible Factor
	 	11/6/2002
	 	Abandoned
	 
	 	 	 	 	 	 	 	 
	10/929,156

	 	US
	 	N-Oxides and
Derivatives of
Melphalan for
Treating Diseased
States Associated
With Hypoxia
Inducible Factor
	 	8/20/2004
	 	Pending
	 
	 	 	 	 	 	 	 	 
	2003291282

	 	AU
	 	N-Oxides and
Derivatives of
Melphalan for
Treating Diseased
States Associated
With Hypoxia
Inducible Factor
	 	11/3/2003
	 	Pending
	 
	 	 	 	 	 	 	 	 
	2504496

	 	CA
	 	N-Oxides and
Derivatives of
Melphalan for
Treating Diseased
States Associated
With Hypoxia
Inducible Factor
	 	11/3/2003
	 	Pending
	 
	 	 	 	 	 	 	 	 

 

 

	 	 	 	 	 	 	 	 	 
	Serial No.	 	Territory	 	Title	 	Filing Date	 	Status
	03768672.2

	 	EP
	 	N-Oxides and
Derivatives of
Melphalan for
Treating Diseased
States Associated
With Hypoxia
Inducible Factor
	 	11/3/2003
	 	Pending
	 
	 	 	 	 	 	 	 	 
	2004-551738

	 	JP
	 	N-Oxides and
Derivatives of
Melphalan for
Treating Diseased
States Associated
With Hypoxia
Inducible Factor
	 	11/3/2003
	 	Pending
	 
	 	 	 	 	 	 	 	 
	2005-004845

	 	MX
	 	N-Oxides and
Derivatives of
Melphalan for
Treating Diseased
States Associated
With Hypoxia
Inducible Factor
	 	11/3/2003
	 	Pending
	 
	 	 	 	 	 	 	 	 
	PCT/US03/35266

	 	PCT
	 	N-Oxides and
Derivatives of
IVielphalan for
Treating Diseased
States Associated
With Hypoxia
Inducible Factor
	 	11/3/2003
	 	Pending
	 
	 	 	 	 	 	 	 	 
	60/487,562

	 	US
	 	Regulation of HIF
Protein Levels via
Deubiquination
Pathway
	 	7/14/2003
	 	Expired
	 
	 	 	 	 	 	 	 	 
	PCT/US04/22656

	 	PCT
	 	Regulation of HIF
Protein Levels via
Deubiquination
Pathway
	 	7/14/2004
	 	Pending
	 
	 	 	 	 	 	 	 	 
	60/602,151

	 	US
	 	Method of
Pre-selecting
Patients for
Anti-VEGF,
Anti-H1F-1 or
Anti-Thioredoxin
Therapy
	 	8/17/2004
	 	Expired
	 
	 	 	 	 	 	 	 	 
	60/602,163

	 	US
	 	Monitoring Effects
of PX-12 on Tumor
Vascular
Permeability
	 	8/17/2004
	 	Expired
	 
	 	 	 	 	 	 	 	 
	11/206,526

	 	US
	 	Method of
Preselecting
Patients for
Anti-VEGF,
Anti-H1F-1 or
Anti-Thioredoxin
Therapy
	 	8/17/2005
	 	Pending
	 
	 	 	 	 	 	 	 	 
	PCT/US05/29416

	 	PCT
	 	Method of
Preselection
Patients for
Anti-VEGF, Anti-
H1F-1 or
Anti-Thioredoxin
Therapy
	 	8/17/2005
	 	Reg./nat. Phases
entered
	 
	 	 	 	 	 	 	 	 
	2005277350

	 	AU
	 	Method of
Preselection
Patients for
Anti-VEGF,
Anti-H1F-1 or
Anti-Thioredoxin
Therapy
	 	8/17/2005
	 	Pending
	 
	 	 	 	 	 	 	 	 
	2,577,312

	 	CA
	 	Method of
Preselection
Patients for
Anti-VEGF,
Anti-HIF-1 or
Anti-Thioredoxin
Therapy
	 	8/17/2005
	 	Pending
	 
	 	 	 	 	 	 	 	 
	05808798.2

	 	EP
	 	Method of
Preselection
Patients for
Anti-VEGF,
Anti-HIF-1 or
Anti-Thioredoxin
Therapy
	 	8/17/2005
	 	Pending

     2. All other terms of the Agreement shall remain the same.

[signature page follows]

 

 

     IN WITNESS WHEREOF, a duly authorized officer of each party hereto has executed this Second
Amendment in duplicate originals by on the day and year below written.

	 	 	 	 	 	 	 

	ARIZONA BOARD OF REGENTS 

On behalf of 

THE UNIVERSITY OF ARIZONA	 	ONCOTHYREON, INC.
	 
	 	 	 	 	 	 
	By:

	 	 /s/ Patrick L. Jones, PhD, MBA
	 	By:
	 	/s/ Robert L. Kirkman, MD
	 

	 	 
	 	 	 	 
	 	 	Name: Patrick L. Jones, PhD, MBA

	 	 	 	Name: Robert L. Kirkman, MD

	 	 	Title:   Director, Office of Technology
Transfer

	 	 	 	Title:   President and CEO

	 
	 	 	 	 	 	 
	Date: 12th July 2010

	 	Date: 13th August 2010exv10w19

December 23, 2010

Ms. Julie Meringer

48 Hurd Road

Belmont, MA 02478

Dear Julie:

This letter acknowledges your separation from employment with Forrester Research, Inc. (“Forrester”
or the “Company”), and sets forth Forrester’s agreement with you concerning this separation and the
terms of your severance package.

You have agreed to resign from your position as Managing Director — IT Client Group and as an
officer of Forrester effective December 3, 2010. Your separation from employment with Forrester
shall be effective as of January 3, 2011 (the “Separation Date”).

On the Separation Date, Forrester will pay you an amount equal to any earned but previously unpaid
base pay through such date, and payment for accrued but unused vacation, reduced by all appropriate
withholdings. Such payments are not contingent upon your execution of this letter agreement.

In addition, subject to your eligibility to elect continuing group health and dental insurance
coverage in accordance with the federal law known as COBRA, your participation in all employee
benefit plans and programs provided by Forrester shall terminate effective January 3, 2011, in
accordance with the terms of such plans and programs.

This letter does not alter the terms of any Company stock option plans (such as the Company’s 1996
Equity Incentive Plan or 2006 Equity Incentive Plan), or the terms of any previously awarded grants
under such plans.

Further, in consideration of your fulfillment of your obligations set forth herein, and without
admission of any wrongdoing or liability on the part of Forrester, you and Forrester agree as
follows:

Headquarters: Forrester Research, Inc. 6 400 Technology Square, Cambridge, MA 02139 USA 6 +1 617/613-6000 6 Fax: +1 617/613-5000

www.forrester.com

 

 

	1.	 	Subject to your execution and non-revocation of this letter agreement, as well as your
continuing fulfillment of all of your obligations hereunder, Forrester will provide you with
the following:

(a) Forrester will pay you severance compensation equal to twenty-four (24) pay periods of
your current base pay ($252,000.00 annually, or $10,500.00 per semi-monthly pay period),
less all applicable withholdings, in accordance with Forrester’s regular semi-monthly
payroll practices. These payments will begin as soon as administratively possible
following the expiration of the revocation period set forth in paragraph 9, below.

(b) Forrester will pay to you an amount equal to twenty-four (24) pay periods of the
Company’s portion of your medical and dental benefits (an aggregate of $17,249.88, or
$718.75 per semi-monthly pay period), less any applicable withholdings, in accordance with
Forrester’s regular semi-monthly payroll practices. These payments will begin as soon as
administratively possible following the expiration of the revocation period set forth in
paragraph 9, below.

(c) On or before March 15, 2011, Forrester will pay to you, in accordance with its normal
payroll practices and less applicable withholdings, your 2010 executive incentive bonus
payment, the specific amount of which will be determined by Forrester’s assessment of your
achievement of your previously set 2010 goals and is subject to approval by the Company’s
Board of Directors.

(d) You will be eligible to receive executive level outplacement services, up to a
maximum amount of $30,000.00, through an entity of your choosing, subject to Forrester’s
approval, which approval shall not be unreasonably withheld. The invoices for such
services shall be sent directly to my attention at Forrester for payment.

(e) You may keep the company-issued laptop that was provided to you during the course of
your employment with Forrester.

	2.	 	You acknowledge that you have returned to Forrester all telephone cards, credit cards,
building cards, keys, work papers, files and other documentation, and other equipment
(exclusive of the company-issued laptop computer which you may keep), computer files and
diskettes, and all other Forrester records and property, without retaining any copies or
derivations thereof.
	 
	3.	 	You have agreed to submit for reimbursement purposes all business expense reports and any
necessary supporting documentation to Forrester by December 31, 2010. The severance pay set
forth in paragraph 1(a) above will take into account a proper reconciliation of amounts due to
you from Forrester and/or amounts due to Forrester from you. These reconciliation adjustments
may include, but are not limited to, outstanding travel advances or expenses, overdue American
Express bills, unreturned Company-owned equipment, and outstanding

2

 

	 	 	expense reports. For the avoidance of doubt, in the event these obligations to Forrester
have not been previously satisfied, Forrester will offset them against any severance
compensation payable hereunder.
	 
	4.	 	The Company affirms its prior agreement to defend and indemnify you relative to any tax
liability relating to your expatriate assignment in London, England from 2000 — 2002;
provided, however, that the Company will have no responsibility to so indemnify you if it is
determined that such tax liability was a result of your intentional misconduct, your improper
reporting, or your undue delay in providing necessary documents to the Company or its tax
advisors. You agree to promptly notify the Company in the event you are served with a levy,
audit notice, summons, subpoena or other legal process regarding any potential tax liability
for this time period.
	 
	5.	 	In consideration of the undertakings described herein, including the severance compensation
which Forrester has agreed to pay you hereunder, and to which you would not otherwise be
entitled, you, on behalf of yourself and your representatives, assigns, executors,
administrators, and heirs, hereby completely release and forever discharge Forrester Research,
Inc. and its subsidiaries, and all of their respective shareholders, officers, and all other
representatives, agents, directors, employees, employee benefit plans, successors, and
assigns, both individually and in their official capacities, from all claims, rights, demands,
actions, obligations, and causes of action, of every kind, nature, and character, known or
unknown, which you now have, may now have, or have ever had, against them arising from or in
any way connected with your employment relationship with Forrester Research, Inc., any actions
during the relationship, and/or the termination of such relationship. This release extends
to, without limitation, “wrongful discharge” claims; all claims relating to any contracts of
employment, express or implied; any claims related to defamation, privacy, misrepresentation,
or breach of the covenant of good faith and fair dealing, express or implied, and tort claims
of every nature; any claims under municipal, state, or federal statutes or ordinances; claimed
violations of fair employment practices, anti-discrimination, or civil rights laws (including
but not limited to all claims under Title VII of the Civil Rights Act of 1964, and any claims
of discrimination on the basis of race, sex, pregnancy, age, religion, national origin, sexual
orientation or sexual preference, handicap, disability, veteran status or any other protected
classification; claims under the Age Discrimination in Employment Act, as amended; claims
under the Family and Medical Leave Act, as amended, or any other federal or state law
concerning leaves of absence; claims under the Americans With Disabilities Act, as amended,
and any other laws and regulations relating to employment discrimination); claims under the
Worker Adjustment and Retraining Notification (“WARN”) Act; claims under the Employee
Retirement Income Security Act (other than claims against an employee benefit plan seeking
payment of a vested benefit under the terms of that plan); claims for wages, bonuses,
incentive compensation, stock payments, stock options, any form of equity participation, or
any other compensation or benefits;

3

 

	 	 	and claims for compensatory or punitive damages or attorney’s fees. This release does not
apply to any vested stock options nor does it alter the terms of any stock option plans or
previously awarded grants under such plans.
	 
	6.	 	You agree that the terms of this letter agreement are confidential. All information relating
to the subject matter of this agreement, including the terms and amounts set forth herein,
have been and will be held confidential by you and not publicized or disclosed to any person
(other than an immediate family member, legal counsel, or financial advisor, provided that any
such individual to whom permissible disclosure is made agrees to be bound by these
confidentiality obligations), business entity, or government agency (except as mandated by
state or federal law). You also agree that you have not and will not disparage Forrester or
any of those connected with it. You represent that, as of the date of this letter agreement,
you have not breached the Employee Confidentiality, Proprietary Rights and Noncompetition
Agreement you entered into with Forrester, and you further agree to abide by such Agreement
going forward. Any breach of this letter agreement or the Employee Confidentiality,
Proprietary Rights and Noncompetition Agreement will be grounds for immediate termination
and/or disgorgement of any of the pay and benefits provided to you hereunder.
	 
	7.	 	Massachusetts law shall govern the validity and interpretation of this agreement.
	 
	8.	 	Any term or provision of this letter agreement that is determined to be invalid or
unenforceable by any court of competent jurisdiction shall, as to such jurisdiction, be
ineffective to the extent of such invalidity or unenforceability without rendering invalid or
unenforceable the remaining terms and provisions of this letter agreement or affecting the
validity or enforceability of any of the terms or provisions of this letter agreement in any
other jurisdiction; and any such invalid or unenforceable provision shall be modified by such
court so that it is enforceable to the greatest extent permitted by applicable law.
	 
	9.	 	This letter agreement constitutes the entire understanding of the parties with respect to
your employment, its termination, and all related matters, excepting only the Employee
Confidentiality, Proprietary Rights and Noncompetition Agreement that will remain in full
force and effect according to its terms. You and Forrester expressly warrant that each has
read and fully understands this agreement; that Forrester has advised you to consult with an
attorney before signing this agreement, and that you have had the opportunity to consult with
legal counsel of your own choosing and to have the terms of this agreement fully explained to
you; that you are not executing this agreement in reliance on any promises, representations,
or inducements other than those contained herein; and that you are executing this agreement
knowingly and voluntarily, and free of any duress or coercion. You may take up to twenty-one
(21) days from the date of your receipt of this letter agreement to decide to sign and return
this agreement to Forrester, provided that you may not sign this letter agreement until the
day following the Separation Date. The offer contained in this letter agreement will

4

 

	 	 	automatically become null and void if Forrester does not receive your signed acceptance in
this twenty-one (21) day time frame. Additionally, for a period of seven (7) days after
you sign this agreement, you may revoke your acceptance of this agreement by delivery of
written notice to Gail S. Mann, Chief Legal Officer, Forrester Research, Inc., 400
Technology Square, Cambridge, MA 02139. This agreement will not take effect until that
revocation period has expired, and provided you have not timely revoked your acceptance of
this agreement.
	 
	10.	 	This letter agreement, and the rights and obligations of the Company and you hereunder, shall
inure to the benefit of and shall be binding upon, you and your heirs and representatives.

If you wish to accept this agreement, please sign the enclosed copy of this letter agreement no
earlier than the day following the Separation Date and within twenty-one
(21) days of your receipt of this letter agreement, and return it to me. Please call me if you
have any questions regarding the information set forth in this letter agreement.

Very truly yours,

	 	 	 

	/s/ Elizabeth Lemons
 

Elizabeth Lemons 

Chief People Officer

	 	 

Accepted and Agreed:

	 	 	 

	/s/ Julie Meringer
 

Julie Meringer

	 	 

January 4, 2011

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00186-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00186-of-00352.parquet"}]]